Detalhe da pesquisa
1.
Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers.
Br J Clin Pharmacol
; 82(1): 83-91, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26914703
2.
Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
Drug Metab Lett
; 12(1): 68-70, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29676238
3.
Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
Fundam Clin Pharmacol
; 30(2): 153-61, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26947771